+

WO2005111621A3 - Squelettes moleculaires pour les epitopes de vih-1 - Google Patents

Squelettes moleculaires pour les epitopes de vih-1 Download PDF

Info

Publication number
WO2005111621A3
WO2005111621A3 PCT/US2005/011928 US2005011928W WO2005111621A3 WO 2005111621 A3 WO2005111621 A3 WO 2005111621A3 US 2005011928 W US2005011928 W US 2005011928W WO 2005111621 A3 WO2005111621 A3 WO 2005111621A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
methods
epitopes
antibodies
subject
Prior art date
Application number
PCT/US2005/011928
Other languages
English (en)
Other versions
WO2005111621A2 (fr
Inventor
Julie M Decker
Beatrice H Hahn
James E Robinson
George M Shaw
Frederic Bibollett-Ruche
Original Assignee
Uab Research Foundation
Administrators Of Tulane Educa
Julie M Decker
Beatrice H Hahn
James E Robinson
George M Shaw
Frederic Bibollett-Ruche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, Administrators Of Tulane Educa, Julie M Decker, Beatrice H Hahn, James E Robinson, George M Shaw, Frederic Bibollett-Ruche filed Critical Uab Research Foundation
Priority to US11/578,761 priority Critical patent/US8637234B2/en
Publication of WO2005111621A2 publication Critical patent/WO2005111621A2/fr
Publication of WO2005111621A3 publication Critical patent/WO2005111621A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des procédés et des compositions destinés à s'utiliser avec un polypeptide d'enveloppe ou une variante fonctionnelle de celui-ci provenant d'un lentivirus qui n'est pas VIH-1 en tant que squelette moléculaire pour les épitopes de VIH-1. Les épitopes de VIH-1 peuvent être reconnus par des anticorps se liant à VIH-1, des anticorps neutralisant VIH-1 et/ou des anticorps induits par CD4. L'invention concerne aussi des procédés pour détecter les anticorps se liant à VIH-1 chez un sujet infecté par VIH-1. En outre, l'invention porte sur des procédés pour déterminer un épitope pour un anticorps se liant à VIH-1; des procédés de dosage pour un anticorps se liant à VIH-1; des procédés pour identifier un mimétique CD4 soluble; des procédés pour neutraliser un virus non-VIH-1; des dosages diagnostiques pour surveiller la maladie VIH chez un sujet ou pour surveiller la réaction du sujet à l'immunisation à un vaccin VIH; et des procédés pour modifier le potentiel de neutralisation d'un anticorps induit par un CD4 dérivé de VIH-1. L'invention concerne aussi des polypeptides chimères, des polynucléotides chimères, des kits, des cellules et des virus.
PCT/US2005/011928 2004-04-16 2005-04-08 Squelettes moleculaires pour les epitopes de vih-1 WO2005111621A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/578,761 US8637234B2 (en) 2004-04-16 2005-04-08 Molecular scaffolds for HIV-1 epitopes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56282404P 2004-04-16 2004-04-16
US60/562,824 2004-04-16
US60605304P 2004-08-31 2004-08-31
US60/606,053 2004-08-31
US64955105P 2005-02-03 2005-02-03
US60/649,551 2005-02-03

Publications (2)

Publication Number Publication Date
WO2005111621A2 WO2005111621A2 (fr) 2005-11-24
WO2005111621A3 true WO2005111621A3 (fr) 2006-02-09

Family

ID=35351710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011928 WO2005111621A2 (fr) 2004-04-16 2005-04-08 Squelettes moleculaires pour les epitopes de vih-1

Country Status (2)

Country Link
US (1) US8637234B2 (fr)
WO (1) WO2005111621A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091455A2 (fr) * 2005-02-18 2006-08-31 Uab Research Foundation Echafaudages moleculaires destines a des immunogenes hiv-1
US8475799B2 (en) 2007-08-09 2013-07-02 University Of Medicine And Dentistry Of New Jersey HIV-1 GP41 neutralization domain and use thereof
EP2238165B1 (fr) 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anticorps à domaine anti-vih et procédé de fabrication et d'utilisation de ceux-ci
US20120034254A1 (en) * 2008-02-07 2012-02-09 Kwong Peter D Antigenic cloaking and its use
US20130195904A1 (en) * 2010-01-04 2013-08-01 National University Of Singapore Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
EP2558128B1 (fr) * 2010-04-14 2016-12-21 Roger Williams Medical Center Méthodes et compositions pour le traitement du vih
EP2571898B1 (fr) 2010-05-21 2021-07-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Cd4 humain à domaine unique, soluble, complètement fonctionnel, à haute affinité, anticorps et protéines hybrides associées
WO2013039792A1 (fr) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogènes à base d'un épitope vih-1 gp120 v1v2
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP4421177A3 (fr) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Protéines f de rsv pré-fusion et leur utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912176A (en) * 1996-06-03 1999-06-15 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre and post exposure protection from infection by HIV
US6328973B1 (en) * 1993-05-07 2001-12-11 Devico Anthony L. Method of raising neutralizing antibodies against HIV
WO2003033666A2 (fr) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328973B1 (en) * 1993-05-07 2001-12-11 Devico Anthony L. Method of raising neutralizing antibodies against HIV
US5912176A (en) * 1996-06-03 1999-06-15 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre and post exposure protection from infection by HIV
WO2003033666A2 (fr) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BREUER J ET AL: "HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2) ENV GENE ANALYSIS: PREDICTION OF GLYCOPROTEIN EPITOPES IMPORTANT FOR HETEROTYPIC NEUTRALIZATION AND EVIDENCE FOR THREE GENOTYPE CLUSTERS WITHIN THE HIV-2A SUBTYPE", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 76, no. PART 2, February 1995 (1995-02-01), pages 333 - 345, XP009028952, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
WO2005111621A2 (fr) 2005-11-24
US20080096187A1 (en) 2008-04-24
US8637234B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
Tomaras et al. Complex immune correlates of protection in HIV‐1 vaccine efficacy trials
Tea et al. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
Astronomo et al. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120
Richard et al. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses
Butler et al. A sample-sparing multiplexed ADCP assay
Liu et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
Gray et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection
Wang et al. Efficient on-chip isolation of HIV subtypes
Gómez-Román et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity
Cheng et al. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting
Hessell et al. Achieving potent autologous neutralizing antibody responses against tier 2 HIV-1 viruses by strategic selection of envelope immunogens
Chung et al. The utility of ADCC responses in HIV infection
WO2005111621A3 (fr) Squelettes moleculaires pour les epitopes de vih-1
Wec et al. Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
Khurana et al. H5N1-SeroDetect EIA and rapid test: a novel differential diagnostic assay for serodiagnosis of H5N1 infections and surveillance
Nkolola et al. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer
Kulkarni et al. Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of envelope and a region from Tat protein
Mkhize et al. Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women
Vaine et al. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies
Saunders et al. SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys
Graham et al. Kinetics and isotype assessment of antibodies targeting the spike protein receptor binding domain of SARS-CoV-2 in COVID-19 patients as a function of age and biological sex
Madhavi et al. Effect of combination antiretroviral therapy on HIV-1-specific antibody-dependent cellular cytotoxicity responses in subtype B-and subtype C-infected cohorts
De Wolf et al. Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2
Wood et al. Domestic cat microsphere immunoassays: Detection of antibodies during feline immunodeficiency virus infection
Tagmyer et al. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 11578761

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载